APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostate Cancer Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Prostate Cancer Vaccines Market Outlook and Growth Opportunities 2026

19 December 2025204 pages

Choose your research edition.

Industry ResearchProstate Cancer Vaccines Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Cancer Vaccines Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Prostate Cancer Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Cancer Vaccines Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Cancer Vaccines Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Prostate Cancer Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Prostate Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prostate Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prostate Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Prostate Cancer Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Prostate Cancer Vaccines market include Pfizer Inc., Vaccitech, Vaccibody AS, Ultimovacs, UbiVac, SOTIO, Sensei Biotherapeutics, Oncovir Inc. and OncBioMune Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Prostate Cancer Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostate Cancer Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostate Cancer Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prostate Cancer Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Prostate Cancer Vaccines Segment by Company

Pfizer Inc.

Vaccitech

Vaccibody AS

Ultimovacs

UbiVac

SOTIO

Sensei Biotherapeutics

Oncovir Inc.

OncBioMune Pharmaceuticals

Momotaro-Gene Inc.

Mediolanum Farmaceutici

Medigene AG

Dendreon Corporation

Curevac AG

Cleveland BioLabs Inc.

Bavarian Nordic

AlphaVax Inc.

Advaxis immunotherapies

Advantagene

Prostate Cancer Vaccines Segment by Type

Tablet

Injection

Prostate Cancer Vaccines Segment by Application

Hospital

Clinic

Others

Prostate Cancer Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Prostate Cancer Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Prostate Cancer Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prostate Cancer Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Prostate Cancer Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Prostate Cancer Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostate Cancer Vaccines industry.

Chapter 3: Detailed analysis of Prostate Cancer Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Prostate Cancer Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Prostate Cancer Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prostate Cancer Vaccines Industry Trends Table 2. Prostate Cancer Vaccines Industry Drivers Table 3. Prostate Cancer Vaccines Industry Opportunities and Challenges Table 4. Prostate Cancer Vaccines Industry Restraints Table 5. Global Prostate Cancer Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prostate Cancer Vaccines Revenue Share by Company (2021-2026) Table 7. Global Prostate Cancer Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Prostate Cancer Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Prostate Cancer Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Prostate Cancer Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Prostate Cancer Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Prostate Cancer Vaccines Company, Product Type & Application Table 13. Global Prostate Cancer Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Prostate Cancer Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablet Table 18. Significant Companies of Injection Table 19. Global Prostate Cancer Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Prostate Cancer Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Prostate Cancer Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Prostate Cancer Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Prostate Cancer Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Prostate Cancer Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Prostate Cancer Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Prostate Cancer Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Prostate Cancer Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Prostate Cancer Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global Prostate Cancer Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Prostate Cancer Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Prostate Cancer Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Prostate Cancer Vaccines Sales Volume Share by Application (2021-2026) Table 36. Global Prostate Cancer Vaccines Sales Volume Share by Application (2027-2032) Table 37. Global Prostate Cancer Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Prostate Cancer Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Prostate Cancer Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Prostate Cancer Vaccines Sales Value Share by Application (2021-2026) Table 41. Global Prostate Cancer Vaccines Sales Value Share by Application (2027-2032) Table 42. Global Prostate Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Prostate Cancer Vaccines Sales by Region (2021-2026) & (K Units) Table 44. Global Prostate Cancer Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Prostate Cancer Vaccines Sales by Region (2027-2032) & (K Units) Table 46. Global Prostate Cancer Vaccines Sales Market Share by Region (2027-2032) Table 47. Global Prostate Cancer Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Prostate Cancer Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Prostate Cancer Vaccines Sales Value Share by Region (2021-2026) Table 50. Global Prostate Cancer Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Prostate Cancer Vaccines Sales Value Share by Region (2027-2032) Table 52. Global Prostate Cancer Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Prostate Cancer Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Prostate Cancer Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Prostate Cancer Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units) Table 57. Global Prostate Cancer Vaccines Sales Market Share by Country (2021-2026) Table 58. Global Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units) Table 59. Global Prostate Cancer Vaccines Sales Market Share by Country (2027-2032) Table 60. Global Prostate Cancer Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Prostate Cancer Vaccines Sales Value Market Share by Country (2021-2026) Table 62. Global Prostate Cancer Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Prostate Cancer Vaccines Sales Value Market Share by Country (2027-2032) Table 64. Pfizer Inc. Company Information Table 65. Pfizer Inc. Business Overview Table 66. Pfizer Inc. Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Pfizer Inc. Prostate Cancer Vaccines Product Portfolio Table 68. Pfizer Inc. Recent Development Table 69. Vaccitech Company Information Table 70. Vaccitech Business Overview Table 71. Vaccitech Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Vaccitech Prostate Cancer Vaccines Product Portfolio Table 73. Vaccitech Recent Development Table 74. Vaccibody AS Company Information Table 75. Vaccibody AS Business Overview Table 76. Vaccibody AS Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Vaccibody AS Prostate Cancer Vaccines Product Portfolio Table 78. Vaccibody AS Recent Development Table 79. Ultimovacs Company Information Table 80. Ultimovacs Business Overview Table 81. Ultimovacs Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Ultimovacs Prostate Cancer Vaccines Product Portfolio Table 83. Ultimovacs Recent Development Table 84. UbiVac Company Information Table 85. UbiVac Business Overview Table 86. UbiVac Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. UbiVac Prostate Cancer Vaccines Product Portfolio Table 88. UbiVac Recent Development Table 89. SOTIO Company Information Table 90. SOTIO Business Overview Table 91. SOTIO Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. SOTIO Prostate Cancer Vaccines Product Portfolio Table 93. SOTIO Recent Development Table 94. Sensei Biotherapeutics Company Information Table 95. Sensei Biotherapeutics Business Overview Table 96. Sensei Biotherapeutics Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Sensei Biotherapeutics Prostate Cancer Vaccines Product Portfolio Table 98. Sensei Biotherapeutics Recent Development Table 99. Oncovir Inc. Company Information Table 100. Oncovir Inc. Business Overview Table 101. Oncovir Inc. Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Oncovir Inc. Prostate Cancer Vaccines Product Portfolio Table 103. Oncovir Inc. Recent Development Table 104. OncBioMune Pharmaceuticals Company Information Table 105. OncBioMune Pharmaceuticals Business Overview Table 106. OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. OncBioMune Pharmaceuticals Prostate Cancer Vaccines Product Portfolio Table 108. OncBioMune Pharmaceuticals Recent Development Table 109. Momotaro-Gene Inc. Company Information Table 110. Momotaro-Gene Inc. Business Overview Table 111. Momotaro-Gene Inc. Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Momotaro-Gene Inc. Prostate Cancer Vaccines Product Portfolio Table 113. Momotaro-Gene Inc. Recent Development Table 114. Mediolanum Farmaceutici Company Information Table 115. Mediolanum Farmaceutici Business Overview Table 116. Mediolanum Farmaceutici Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Mediolanum Farmaceutici Prostate Cancer Vaccines Product Portfolio Table 118. Mediolanum Farmaceutici Recent Development Table 119. Medigene AG Company Information Table 120. Medigene AG Business Overview Table 121. Medigene AG Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Medigene AG Prostate Cancer Vaccines Product Portfolio Table 123. Medigene AG Recent Development Table 124. Dendreon Corporation Company Information Table 125. Dendreon Corporation Business Overview Table 126. Dendreon Corporation Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Dendreon Corporation Prostate Cancer Vaccines Product Portfolio Table 128. Dendreon Corporation Recent Development Table 129. Curevac AG Company Information Table 130. Curevac AG Business Overview Table 131. Curevac AG Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Curevac AG Prostate Cancer Vaccines Product Portfolio Table 133. Curevac AG Recent Development Table 134. Cleveland BioLabs Inc. Company Information Table 135. Cleveland BioLabs Inc. Business Overview Table 136. Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Cleveland BioLabs Inc. Prostate Cancer Vaccines Product Portfolio Table 138. Cleveland BioLabs Inc. Recent Development Table 139. Bavarian Nordic Company Information Table 140. Bavarian Nordic Business Overview Table 141. Bavarian Nordic Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Bavarian Nordic Prostate Cancer Vaccines Product Portfolio Table 143. Bavarian Nordic Recent Development Table 144. AlphaVax Inc. Company Information Table 145. AlphaVax Inc. Business Overview Table 146. AlphaVax Inc. Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. AlphaVax Inc. Prostate Cancer Vaccines Product Portfolio Table 148. AlphaVax Inc. Recent Development Table 149. Advaxis immunotherapies Company Information Table 150. Advaxis immunotherapies Business Overview Table 151. Advaxis immunotherapies Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Advaxis immunotherapies Prostate Cancer Vaccines Product Portfolio Table 153. Advaxis immunotherapies Recent Development Table 154. Advantagene Company Information Table 155. Advantagene Business Overview Table 156. Advantagene Prostate Cancer Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Advantagene Prostate Cancer Vaccines Product Portfolio Table 158. Advantagene Recent Development Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Prostate Cancer Vaccines Distributors List Table 162. Prostate Cancer Vaccines Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Prostate Cancer Vaccines Product Image Figure 2. Global Prostate Cancer Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostate Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Prostate Cancer Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Prostate Cancer Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Prostate Cancer Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablet Image Figure 10. Injection Image Figure 11. Global Prostate Cancer Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Prostate Cancer Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Prostate Cancer Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Prostate Cancer Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Prostate Cancer Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Prostate Cancer Vaccines Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Prostate Cancer Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Prostate Cancer Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Prostate Cancer Vaccines Sales Volume Share by Application (2021-2032) Figure 23. Global Prostate Cancer Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Prostate Cancer Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Prostate Cancer Vaccines Sales Value Share by Application (2021-2032) Figure 26. Global Prostate Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Prostate Cancer Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Prostate Cancer Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Prostate Cancer Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Prostate Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. North America Prostate Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Prostate Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Prostate Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Prostate Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Prostate Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Prostate Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. South America Prostate Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Prostate Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Prostate Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Prostate Cancer Vaccines Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Prostate Cancer Vaccines Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Injection
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Pfizer Inc.
  • Vaccitech
  • Vaccibody AS
  • Ultimovacs
  • UbiVac
  • SOTIO
  • Sensei Biotherapeutics
  • Oncovir Inc.
  • OncBioMune Pharmaceuticals
  • Momotaro-Gene Inc.
  • Mediolanum Farmaceutici
  • Medigene AG
  • Dendreon Corporation
  • Curevac AG
  • Cleveland BioLabs Inc.
  • Bavarian Nordic
  • AlphaVax Inc.
  • Advaxis immunotherapies
  • Advantagene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prostate Cancer Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Prostate Cancer Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Prostate Cancer Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Prostate Cancer Vaccines Market Dynamics
  1. 2.1 Prostate Cancer Vaccines Industry Trends
  2. 2.2 Prostate Cancer Vaccines Industry Drivers
  3. 2.3 Prostate Cancer Vaccines Industry Opportunities and Challenges
  4. 2.4 Prostate Cancer Vaccines Industry Restraints
3 Prostate Cancer Vaccines Market by Company
  1. 3.1 Global Prostate Cancer Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Prostate Cancer Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Prostate Cancer Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Prostate Cancer Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Prostate Cancer Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Prostate Cancer Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Prostate Cancer Vaccines Company Product Type and Application
  8. 3.8 Global Prostate Cancer Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Prostate Cancer Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Prostate Cancer Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Prostate Cancer Vaccines Market by Type
  1. 4.1 Prostate Cancer Vaccines Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Injection
  4. 4.2 Global Prostate Cancer Vaccines Sales Volume by Type
  5. 4.2.1 Global Prostate Cancer Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Prostate Cancer Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Prostate Cancer Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Prostate Cancer Vaccines Sales Value by Type
  9. 4.3.1 Global Prostate Cancer Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Prostate Cancer Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Prostate Cancer Vaccines Sales Value Share by Type (2021-2032)
5 Prostate Cancer Vaccines Market by Application
  1. 5.1 Prostate Cancer Vaccines Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Prostate Cancer Vaccines Sales Volume by Application
  6. 5.2.1 Global Prostate Cancer Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Prostate Cancer Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Prostate Cancer Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Prostate Cancer Vaccines Sales Value by Application
  10. 5.3.1 Global Prostate Cancer Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Prostate Cancer Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global Prostate Cancer Vaccines Sales Value Share by Application (2021-2032)
6 Prostate Cancer Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Prostate Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prostate Cancer Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Prostate Cancer Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Prostate Cancer Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Prostate Cancer Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Prostate Cancer Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Prostate Cancer Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Prostate Cancer Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Prostate Cancer Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Prostate Cancer Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Prostate Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Prostate Cancer Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Prostate Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Prostate Cancer Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Prostate Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Prostate Cancer Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Prostate Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Prostate Cancer Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Prostate Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
7 Prostate Cancer Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Prostate Cancer Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prostate Cancer Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Prostate Cancer Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Prostate Cancer Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Prostate Cancer Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Prostate Cancer Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Prostate Cancer Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Prostate Cancer Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Prostate Cancer Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Prostate Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Prostate Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer Inc.
  2. 8.1.1 Pfizer Inc. Company Information
  3. 8.1.2 Pfizer Inc. Business Overview
  4. 8.1.3 Pfizer Inc. Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Inc. Prostate Cancer Vaccines Product Portfolio
  6. 8.1.5 Pfizer Inc. Recent Developments
  7. 8.2 Vaccitech
  8. 8.2.1 Vaccitech Company Information
  9. 8.2.2 Vaccitech Business Overview
  10. 8.2.3 Vaccitech Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Vaccitech Prostate Cancer Vaccines Product Portfolio
  12. 8.2.5 Vaccitech Recent Developments
  13. 8.3 Vaccibody AS
  14. 8.3.1 Vaccibody AS Company Information
  15. 8.3.2 Vaccibody AS Business Overview
  16. 8.3.3 Vaccibody AS Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Vaccibody AS Prostate Cancer Vaccines Product Portfolio
  18. 8.3.5 Vaccibody AS Recent Developments
  19. 8.4 Ultimovacs
  20. 8.4.1 Ultimovacs Company Information
  21. 8.4.2 Ultimovacs Business Overview
  22. 8.4.3 Ultimovacs Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ultimovacs Prostate Cancer Vaccines Product Portfolio
  24. 8.4.5 Ultimovacs Recent Developments
  25. 8.5 UbiVac
  26. 8.5.1 UbiVac Company Information
  27. 8.5.2 UbiVac Business Overview
  28. 8.5.3 UbiVac Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 UbiVac Prostate Cancer Vaccines Product Portfolio
  30. 8.5.5 UbiVac Recent Developments
  31. 8.6 SOTIO
  32. 8.6.1 SOTIO Company Information
  33. 8.6.2 SOTIO Business Overview
  34. 8.6.3 SOTIO Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SOTIO Prostate Cancer Vaccines Product Portfolio
  36. 8.6.5 SOTIO Recent Developments
  37. 8.7 Sensei Biotherapeutics
  38. 8.7.1 Sensei Biotherapeutics Company Information
  39. 8.7.2 Sensei Biotherapeutics Business Overview
  40. 8.7.3 Sensei Biotherapeutics Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sensei Biotherapeutics Prostate Cancer Vaccines Product Portfolio
  42. 8.7.5 Sensei Biotherapeutics Recent Developments
  43. 8.8 Oncovir Inc.
  44. 8.8.1 Oncovir Inc. Company Information
  45. 8.8.2 Oncovir Inc. Business Overview
  46. 8.8.3 Oncovir Inc. Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Oncovir Inc. Prostate Cancer Vaccines Product Portfolio
  48. 8.8.5 Oncovir Inc. Recent Developments
  49. 8.9 OncBioMune Pharmaceuticals
  50. 8.9.1 OncBioMune Pharmaceuticals Company Information
  51. 8.9.2 OncBioMune Pharmaceuticals Business Overview
  52. 8.9.3 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Product Portfolio
  54. 8.9.5 OncBioMune Pharmaceuticals Recent Developments
  55. 8.10 Momotaro-Gene Inc.
  56. 8.10.1 Momotaro-Gene Inc. Company Information
  57. 8.10.2 Momotaro-Gene Inc. Business Overview
  58. 8.10.3 Momotaro-Gene Inc. Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Momotaro-Gene Inc. Prostate Cancer Vaccines Product Portfolio
  60. 8.10.5 Momotaro-Gene Inc. Recent Developments
  61. 8.11 Mediolanum Farmaceutici
  62. 8.11.1 Mediolanum Farmaceutici Company Information
  63. 8.11.2 Mediolanum Farmaceutici Business Overview
  64. 8.11.3 Mediolanum Farmaceutici Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Mediolanum Farmaceutici Prostate Cancer Vaccines Product Portfolio
  66. 8.11.5 Mediolanum Farmaceutici Recent Developments
  67. 8.12 Medigene AG
  68. 8.12.1 Medigene AG Company Information
  69. 8.12.2 Medigene AG Business Overview
  70. 8.12.3 Medigene AG Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Medigene AG Prostate Cancer Vaccines Product Portfolio
  72. 8.12.5 Medigene AG Recent Developments
  73. 8.13 Dendreon Corporation
  74. 8.13.1 Dendreon Corporation Company Information
  75. 8.13.2 Dendreon Corporation Business Overview
  76. 8.13.3 Dendreon Corporation Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Dendreon Corporation Prostate Cancer Vaccines Product Portfolio
  78. 8.13.5 Dendreon Corporation Recent Developments
  79. 8.14 Curevac AG
  80. 8.14.1 Curevac AG Company Information
  81. 8.14.2 Curevac AG Business Overview
  82. 8.14.3 Curevac AG Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Curevac AG Prostate Cancer Vaccines Product Portfolio
  84. 8.14.5 Curevac AG Recent Developments
  85. 8.15 Cleveland BioLabs Inc.
  86. 8.15.1 Cleveland BioLabs Inc. Company Information
  87. 8.15.2 Cleveland BioLabs Inc. Business Overview
  88. 8.15.3 Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Cleveland BioLabs Inc. Prostate Cancer Vaccines Product Portfolio
  90. 8.15.5 Cleveland BioLabs Inc. Recent Developments
  91. 8.16 Bavarian Nordic
  92. 8.16.1 Bavarian Nordic Company Information
  93. 8.16.2 Bavarian Nordic Business Overview
  94. 8.16.3 Bavarian Nordic Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bavarian Nordic Prostate Cancer Vaccines Product Portfolio
  96. 8.16.5 Bavarian Nordic Recent Developments
  97. 8.17 AlphaVax Inc.
  98. 8.17.1 AlphaVax Inc. Company Information
  99. 8.17.2 AlphaVax Inc. Business Overview
  100. 8.17.3 AlphaVax Inc. Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 AlphaVax Inc. Prostate Cancer Vaccines Product Portfolio
  102. 8.17.5 AlphaVax Inc. Recent Developments
  103. 8.18 Advaxis immunotherapies
  104. 8.18.1 Advaxis immunotherapies Company Information
  105. 8.18.2 Advaxis immunotherapies Business Overview
  106. 8.18.3 Advaxis immunotherapies Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Advaxis immunotherapies Prostate Cancer Vaccines Product Portfolio
  108. 8.18.5 Advaxis immunotherapies Recent Developments
  109. 8.19 Advantagene
  110. 8.19.1 Advantagene Company Information
  111. 8.19.2 Advantagene Business Overview
  112. 8.19.3 Advantagene Prostate Cancer Vaccines Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Advantagene Prostate Cancer Vaccines Product Portfolio
  114. 8.19.5 Advantagene Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Prostate Cancer Vaccines Value Chain Analysis
  2. 9.1.1 Prostate Cancer Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Prostate Cancer Vaccines Sales Mode & Process
  6. 9.2 Prostate Cancer Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Prostate Cancer Vaccines Distributors
  9. 9.2.3 Prostate Cancer Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst